MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
416.76%
Quick Ratio
389.00%
Cash Ratio
60.21%
Debt to Asset Ratio
46.28%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term investments
    • Cash and cash equivalents
    • Accounts receivable, net
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Series a convertible preferred s...
    • Others
Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
62,137
54,301
52,078
135,586
Short-term investments
278,488
334,648
363,974
155,444
Accounts receivable, net
34,192
26,081
33,034
26,122
Inventory
28,651
25,753
22,107
18,872
Prepaid expenses and other current assets
26,622
26,133
23,609
24,656
Total current assets
430,090
466,916
494,802
360,680
Property and equipment, net
1,065
1,104
237
297
Right-of-use asset
2,936
3,049
3,158
3,262
Intangible assets, net
5,106
5,319
5,533
5,747
Restricted cash
601
522
671
527
Other long-term assets
2,518
3,286
2,473
2,220
Total assets
442,316
480,196
506,874
372,733
Accounts payable
12,299
13,947
13,631
15,982
Accrued expenses and other current liabilities
80,045
83,855
84,456
69,185
Other current liability - lg chem
-
0
-
40,000
Lease liability
676
650
624
510
Deferred revenue
48
194
-
-
Deferred royalty obligation, current
10,130
7,296
5,556
3,778
Total current liabilities
103,198
105,942
104,267
129,455
Deferred royalty obligation
98,339
100,886
103,409
106,014
Lease liability, non-current
3,163
3,342
3,515
3,681
Derivative liability
-
0
-
-
Total liabilities
204,700
210,170
211,191
239,150
Series a convertible preferred stock, 0.001 par value 150,000 shares authorized 132,500 and 132500 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively. liquidation preference of 132,500 and 132,500 as of march 31, 2026, and december 31, 2025, respectively
114,710
130,957
146,866
145,491
Common stock, 0.001 par value 120,000,000 shares authorized 68,445,084 and 67,205,321 shares issued and outstanding at march31, 2026 and december31, 2025, respectively
69
67
67
64
Additional paid-in capital
1,529,909
1,491,675
1,454,048
1,241,744
Accumulated other comprehensive income (loss)
444
-796
-926
-2,248
Accumulated deficit
-1,407,516
-1,351,877
-1,304,372
-1,251,468
Total stockholders equity
122,906
139,069
148,817
-11,908
Total liabilities, convertible preferred stock and stockholders equity
442,316
480,196
506,874
372,733
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$278,488K Cash and cashequivalents$62,137K Accounts receivable, net$34,192K Inventory$28,651K Prepaid expenses andother current assets$26,622K Total current assets$430,090K Intangible assets, net$5,106K Right-of-use asset$2,936K Other long-termassets$2,518K Property and equipment,net$1,065K Restricted cash$601K Total assets$442,316K Total liabilities,convertible preferred stock...$442,316K Total liabilities$204,700K Total stockholdersequity$122,906K Series a convertiblepreferred stock, 0.001 par...$114,710K Accumulated deficit-$1,407,516K Total currentliabilities$103,198K Deferred royaltyobligation$98,339K Lease liability,non-current$3,163K Additional paid-in capital$1,529,909K Accumulated othercomprehensive income (loss)$444K Common stock, 0.001 parvalue 120,000,000...$69K Accrued expenses andother current...$80,045K Accounts payable$12,299K Deferred royaltyobligation, current$10,130K Lease liability$676K Deferred revenue$48K

RHYTHM PHARMACEUTICALS, INC. (RYTM)

RHYTHM PHARMACEUTICALS, INC. (RYTM)